Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Express Scripts
Medtronic
Colorcon

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Hydrochlorothiazide; labetalol hydrochloride - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for hydrochlorothiazide; labetalol hydrochloride and what is the scope of patent protection?

Hydrochlorothiazide; labetalol hydrochloride is the generic ingredient in two branded drugs marketed by Schering and Glaxosmithkline, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for hydrochlorothiazide; labetalol hydrochloride.

Summary for hydrochlorothiazide; labetalol hydrochloride
US Patents:0
Tradenames:2
Applicants:2
NDAs:2
Drug Master File Entries: 32
Clinical Trials: 1
DailyMed Link:hydrochlorothiazide; labetalol hydrochloride at DailyMed
Recent Clinical Trials for hydrochlorothiazide; labetalol hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
VA Office of Research and DevelopmentN/A

See all hydrochlorothiazide; labetalol hydrochloride clinical trials

US Patents and Regulatory Information for hydrochlorothiazide; labetalol hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-001 Apr 6, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline TRANDATE HCT hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019174-003 Apr 10, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-004 Apr 6, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-002 Apr 6, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline TRANDATE HCT hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019174-004 Apr 10, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline TRANDATE HCT hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019174-001 Apr 10, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for hydrochlorothiazide; labetalol hydrochloride

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKinsey
Colorcon
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.